Pharmaceuticals, Biotechnology and Life Sciences
Data presented by Professor Christophe Le Tourneau at the 2021 Annual Meeting of the American Society for Radiation Oncology First…
Early Clinical Activity and Safety Profile Support Continued Investigation of Repotrectinib in Pediatric Tumors Harboring ALK, ROS1 or NTRK Alterations…
62% vs. 25% overall response rates with navicixizumab plus paclitaxel in biomarker positive vs. biomarker negative patients using the Xerna™ TME…
BUFFALO, N.Y., Oct. 22, 2021 (GLOBE NEWSWIRE) — Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development,…
PHILADELPHIA, Oct. 22, 2021 (GLOBE NEWSWIRE) — Context Therapeutics Inc. (the “Company”) (Nasdaq: CNTX), a women’s oncology company developing advanced…
‒ Susvimo, previously called Port Delivery System with ranibizumab, is the first wet AMD treatment in 15 years to provide…
Positive results from two cohorts of Phase 1/2 clinical trial with NOX-A12 in brain cancer; full readout expected in Q1…
DUBLIN–(BUSINESS WIRE)–The “Transfection Reagents and Equipment Market – Growth, Trends, COVID-19 Impact, and Forecasts (2021 – 2026)” report has been…
DUBLIN–(BUSINESS WIRE)–The “Global PDGFR Inhibitors Market, Drug Sales & Clinical Trials Insight 2026” report has been added to ResearchAndMarkets.com’s offering.…
Sixteen-week results from the Phase 3 ECZTRA 6 trial in adolescents showed tralokinumab 150 mg and 300 mg significantly improved…